

OmvoH IV (mirikizumab-mrkz)

REFERRAL STATUS: New Referral Dose or Frequency Change Order Renewal
Infusion Office Preference: _____

PATIENT INFORMATION			
Date:	Patient Name:	DOB:	
<input type="checkbox"/> NKDA Allergies:	Weight (lbs / kg):	Height:	
Patient Status: <input type="checkbox"/> New to Therapy <input type="checkbox"/> Continuing Therapy - Last Treatment Date:		Next Due Date:	
PROVIDER INFORMATION			
Office Contact Name:		Office Email:	
Prescribing Providers Name:		Provider NPI:	
Office Address:		City:	State: Zip:
Office Phone Number:		Office Fax Number:	
DIAGNOSIS AND ICD 10 CODE			
<input type="checkbox"/> Ulcerative Colitis		ICD-10 Code:	K51.90
<input type="checkbox"/> Crohn's Disease		ICD-10 Code:	K50.90
<input type="checkbox"/> Other Diagnosis:		ICD-10 Code:	
REQUIRED DOCUMENTATION/Testing			
<input type="checkbox"/> This signed order form by the provider <input type="checkbox"/> Patient demographics AND insurance info <input type="checkbox"/> Clinical/Progress notes supporting primary dx		<input type="checkbox"/> Confirmed negative TB testing <input type="checkbox"/> LFT and Bilirubin lab results	
List Tried & Failed Therapies, including duration of treatment: 1) _____ 2) _____			
MEDICATION ORDERS			
Ulcerative Colitis dosing	<input type="checkbox"/> Omvoh 300 mg IV at weeks 0 , 4 , 8		
Crohn's Disease dosing	<input type="checkbox"/> Omvoh 900 mg IV at weeks 0 , 4 , 8		

SPECIAL INSTRUCTIONS

***Hepatotoxicity in treatment of Crohn's disease. Drug induced liver injury during induction has been reported. Monitor LFT's and bilirubin at baseline and during induction, up to at least 24 weeks of treatment. Monitor thereafter according to routine patient management.*

Provider Name (Print)

**Physician Signature:

Date:

Fax referral to 866-507-1164 or email to bionurses@metroinfusioncenter.com

All information contained in this order form is strictly confidential and will become part of the patient's medical record.